Collegium Pharmaceutical (COLL) Amortizatization of Intangibles (2018 - 2026)
Collegium Pharmaceutical's (COLL) quarterly Amortizatization of Intangibles came in at $178000.0 in Q1 2026, down 45.06% year-on-year from $324000.0 in Q1 2025, and down 29.92% quarter-over-quarter from $254000.0 in Q4 2025.
Collegium Pharmaceutical (COLL) Amortizatization of Intangibles (2018 - 2026) Analysis & Trends
Collegium Pharmaceutical's Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $178000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles fell 45.06% year-over-year to $178000.0 in Q1 2026; TTM through Mar 2026 was $926000.0, a 52.19% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 47.14% from the prior year.
- Amortizatization of Intangibles fell to $178000.0 in Q1 2026 per COLL's latest filing, from $254000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $723000.0 in Q2 2024 and bottomed at $178000.0 in Q1 2026.
- The 4-year median for Amortizatization of Intangibles is $376000.0 (2024), against an average of $401363.6.
- Across the five-year window, Amortizatization of Intangibles fell 9.67% in 2024 and tumbled 63.49% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $568000.0 in 2023, then slumped by 33.8% to $376000.0 in 2024, then plunged by 32.45% to $254000.0 in 2025, then dropped by 29.92% to $178000.0 in 2026.
- Per Business Quant, the three latest COLL Amortizatization of Intangibles figures stand at $178000.0 (Q1 2026), $254000.0 (Q4 2025), and $230000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Collegium Pharmaceutical | 1.13 Bn | 843.07 Mn | 117.25 Mn | 178,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 178,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Dec 31, 2025 | 254,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Sep 30, 2025 | 230,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 264,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Mar 31, 2025 | 324,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 514,000.00 |
| Sep 30, 2024 | 514,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Mar 31, 2024 | 415,000.00 |
| Dec 31, 2023 | 568,000.00 |
| Dec 31, 2023 | 568,000.00 |